SG11201501415RA - Orally administered medical composition - Google Patents
Orally administered medical compositionInfo
- Publication number
- SG11201501415RA SG11201501415RA SG11201501415RA SG11201501415RA SG11201501415RA SG 11201501415R A SG11201501415R A SG 11201501415RA SG 11201501415R A SG11201501415R A SG 11201501415RA SG 11201501415R A SG11201501415R A SG 11201501415RA SG 11201501415R A SG11201501415R A SG 11201501415RA
- Authority
- SG
- Singapore
- Prior art keywords
- orally administered
- medical composition
- administered medical
- composition
- orally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012191833 | 2012-08-31 | ||
| PCT/JP2013/073351 WO2014034860A1 (en) | 2012-08-31 | 2013-08-30 | Orally administered medical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501415RA true SG11201501415RA (en) | 2015-05-28 |
Family
ID=50183665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501415RA SG11201501415RA (en) | 2012-08-31 | 2013-08-30 | Orally administered medical composition |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150306090A1 (en) |
| EP (1) | EP2891493A4 (en) |
| JP (1) | JPWO2014034860A1 (en) |
| KR (1) | KR20150045500A (en) |
| CN (1) | CN104602693A (en) |
| AU (1) | AU2013309922A1 (en) |
| BR (1) | BR112015004244A2 (en) |
| CA (1) | CA2883270A1 (en) |
| EA (1) | EA201590449A1 (en) |
| HK (1) | HK1208801A1 (en) |
| IL (1) | IL237423A0 (en) |
| MX (1) | MX2015002633A (en) |
| PH (1) | PH12015500313A1 (en) |
| SG (1) | SG11201501415RA (en) |
| TW (1) | TW201424772A (en) |
| WO (1) | WO2014034860A1 (en) |
| ZA (1) | ZA201501977B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| JP2017078023A (en) * | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | Pharmaceutical composition for oral administration |
| US9956194B2 (en) | 2014-12-03 | 2018-05-01 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| EP3365321B1 (en) | 2015-10-23 | 2023-12-13 | B3AR Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| WO2017186593A1 (en) | 2016-04-25 | 2017-11-02 | Synthon B.V. | Tablets comprising mirabegron and solifenacin |
| US10543174B2 (en) | 2016-04-25 | 2020-01-28 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| CN107397733B (en) * | 2016-05-20 | 2020-02-07 | 山东威智百科药业有限公司 | Mirabegron sustained release tablet and preparation method thereof |
| WO2017210696A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| CN106361715A (en) * | 2016-09-02 | 2017-02-01 | 迪沙药业集团有限公司 | Mirabegron composition |
| KR102051132B1 (en) * | 2017-03-17 | 2019-12-02 | 주식회사 종근당 | Pharmaceutical composition for controlled release comprising Mirabegron or its salts |
| KR101877834B1 (en) * | 2017-04-27 | 2018-07-12 | 주식회사 다산제약 | Novel salts of mirabegron and manufacturing method thereof |
| KR20170088783A (en) * | 2017-07-07 | 2017-08-02 | 지엘팜텍주식회사 | Wetgranulation composition containing mirabegron |
| WO2019013583A2 (en) * | 2017-07-14 | 2019-01-17 | 주식회사 대웅제약 | Pharmaceutical preparation and preparation method therefor |
| KR101937713B1 (en) | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | Pharmaceutical formulation and preparation method for the same |
| US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| KR102018495B1 (en) * | 2018-03-13 | 2019-09-05 | 충북대학교 산학협력단 | Sustained-release bilayer tablets for the treatment of overactive bladder And method for manufacturing the same |
| KR102371567B1 (en) * | 2018-04-06 | 2022-03-07 | 한미약품 주식회사 | Controlled Release Pharmaceutical Composition comprising Mirabegron |
| WO2020097328A1 (en) * | 2018-11-07 | 2020-05-14 | Velicept Therapeutics, Inc | Fixed dose pharmaceutical compositions for treating overactive bladder and related conditions |
| KR102062791B1 (en) * | 2019-02-26 | 2020-01-06 | 신일제약 주식회사 | Pharmaceutical formulation for controlled release containing mirabegron or pharmaceutically acceptable salts thereof as an active ingredient |
| US20210353546A1 (en) * | 2020-05-12 | 2021-11-18 | Jubilant Pharma Holdings Inc. | Dual release pharmaceutical compositions comprising the combination of a beta-3 adrenoreceptor agonist and a muscarinic receptor antagonist |
| EP4159199A1 (en) | 2021-09-29 | 2023-04-05 | Lotus Pharmaceutical Co., Ltd. | Combined formulation of mirabegron and solifenacin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2005012I1 (en) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin and pharmaceutically acceptable salts thereof |
| DE69802832T2 (en) * | 1997-10-03 | 2002-06-20 | Warner Lambert Co | PRESSED NITROGLYCERIN TABLETS AND METHOD FOR THE PRODUCTION THEREOF |
| ID23989A (en) | 1997-10-17 | 2000-06-14 | Yamanouchi Pharma Co Ltd | THE AMIDA DOWNS OR THE SALT |
| US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| CA2503570C (en) | 2002-11-07 | 2011-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| SI2216021T1 (en) | 2007-11-02 | 2013-01-31 | Astellas Pharma Inc. | Pharmaceutical composition for treating overactive bladder |
| TWI478712B (en) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | Pharmaceutical composition for modified release |
| AU2010211725C1 (en) * | 2009-02-04 | 2014-10-16 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
| SG10201506076TA (en) * | 2010-08-03 | 2015-09-29 | Altherx Inc | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| TWI612975B (en) * | 2012-03-02 | 2018-02-01 | 安斯泰來製藥股份有限公司 | Quickly disintegrating tablet |
-
2013
- 2013-08-30 BR BR112015004244A patent/BR112015004244A2/en not_active IP Right Cessation
- 2013-08-30 KR KR1020157007248A patent/KR20150045500A/en not_active Application Discontinuation
- 2013-08-30 AU AU2013309922A patent/AU2013309922A1/en not_active Abandoned
- 2013-08-30 CN CN201380045454.4A patent/CN104602693A/en active Pending
- 2013-08-30 WO PCT/JP2013/073351 patent/WO2014034860A1/en active Application Filing
- 2013-08-30 US US14/423,679 patent/US20150306090A1/en not_active Abandoned
- 2013-08-30 TW TW102131296A patent/TW201424772A/en unknown
- 2013-08-30 SG SG11201501415RA patent/SG11201501415RA/en unknown
- 2013-08-30 JP JP2014533112A patent/JPWO2014034860A1/en active Pending
- 2013-08-30 CA CA2883270A patent/CA2883270A1/en not_active Abandoned
- 2013-08-30 MX MX2015002633A patent/MX2015002633A/en unknown
- 2013-08-30 EA EA201590449A patent/EA201590449A1/en unknown
- 2013-08-30 EP EP13832156.7A patent/EP2891493A4/en not_active Withdrawn
-
2015
- 2015-02-12 PH PH12015500313A patent/PH12015500313A1/en unknown
- 2015-02-25 IL IL237423A patent/IL237423A0/en unknown
- 2015-03-23 ZA ZA2015/01977A patent/ZA201501977B/en unknown
- 2015-09-25 HK HK15109476.7A patent/HK1208801A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104602693A (en) | 2015-05-06 |
| ZA201501977B (en) | 2016-07-27 |
| EP2891493A1 (en) | 2015-07-08 |
| US20150306090A1 (en) | 2015-10-29 |
| KR20150045500A (en) | 2015-04-28 |
| EA201590449A1 (en) | 2015-06-30 |
| AU2013309922A1 (en) | 2015-04-09 |
| CA2883270A1 (en) | 2014-03-06 |
| IL237423A0 (en) | 2015-04-30 |
| EP2891493A4 (en) | 2016-05-18 |
| PH12015500313A1 (en) | 2015-04-20 |
| WO2014034860A1 (en) | 2014-03-06 |
| TW201424772A (en) | 2014-07-01 |
| HK1208801A1 (en) | 2016-03-18 |
| BR112015004244A2 (en) | 2017-07-04 |
| JPWO2014034860A1 (en) | 2016-08-08 |
| MX2015002633A (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208801A1 (en) | Orally administered medical composition | |
| ZA201703992B (en) | Inhalable pharmaceutical compositions | |
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| ZA201501930B (en) | Pharmaceutical composition | |
| HRP20181193T1 (en) | Oral administrable pharmaceutical composition | |
| EP2832730A4 (en) | Mirabegron-containing pharmaceutical composition | |
| HK1199821A1 (en) | Oral pharmaceutical composition | |
| HRP20190050T1 (en) | Pharmaceutical compositions for combination therapy | |
| AP2015008208A0 (en) | Pharmaceutical administration forms comprising | |
| EP2769718A4 (en) | Medicinal composition | |
| EP2897590A4 (en) | Pharmaceutical composition | |
| SG11201504068UA (en) | Orally administered liquid formulation | |
| EP2851078A4 (en) | Pharmaceutical composition | |
| ZA201400751B (en) | Pharmaceutical composition | |
| HUE043019T2 (en) | Pharmaceutical compositions for combination therapy |